Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease

Gastroenterology

Volumn 146, Issue 2, 2014, Pages 383-391

  Walters, Thomas D ^a   Kim, Mi Ok ^b   Denson, Lee A ^b   Griffiths, Anne M ^a   Dubinsky, Marla ^c   Markowitz, James ^d   Baldassano, Robert ^e   Crandall, Wallace ^f   Rosh, Joel ^g   Pfefferkorn, Marian ^h   Otley, Anthony ⁱ   Heyman, Melvin B ^j   Leleiko, Neal ^k   Baker, Susan ^l   Guthery, Stephen L ^m   Evans, Jonathan ⁿ   Ziring, David ^o   Kellermayer, Richard ^p   Stephens, Michael ^q   Mack, David ^r   Oliva Hemker, Maria ^s   Patel, Ashish S ^t   Kirschner, Barbara ^u   Moulton, Dedrick ^v   Cohen, Stanley ^w   Kim, Sandra ^x   Liu, Chunyan ^b   Essers, Jonah ^y   Kugathasan, Subra ^z   Hyams, Jeffrey S ^aa   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Northwell Health   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g Goryeb Children's Hospital   (United States)

^h RILEY CHILDREN S HOSPITAL   (United States)

ⁱ IWK HEALTH CENTRE   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k HASBRO CHILDREN'S HOSPITAL   (United States)

^l CHILDREN S HOSPITAL OF BUFFALO   (United States)

^m PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

ⁿ NEMOURS CHILDREN S CLINIC   (United States)

^o CHILDREN S HOSPITAL LOS ANGELES   (United States)

^p BAYLOR COLLEGE OF MEDICINE   (United States)

^q Children's Hospital of Wisconsin   (United States)

^r CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^s JOHNS HOPKINS UNIVERSITY   (United States)

^t TEXAS CHILDREN S HOSPITAL   (United States)

^u UNIVERSITY OF CHICAGO   (United States)

^v MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^w Children's Healthcare   (United States)

^x UNIVERSITY OF NORTH CAROLINA   (United States)

^y BOSTON CHILDREN S HOSPITAL   (United States)

^z EMORY UNIVERSITY   (United States)

^aa Division of Pediatric Infectious Diseases   (United States)

more..

Author keywords

Drug; Immune Regulation; Infliximab; Pediatric IBD

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ALTERNATIVE MEDICINE; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DRUG EFFICACY; ENTERIC FEEDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

BMI; BODY MASS INDEX; C-REACTIVE PROTEIN; CD; CORTICOSTEROID; CROHN'S DISEASE; CRP; CS; DRUG; IM; IMMUNE REGULATION; IMMUNOMODULATOR; INFLIXIMAB; PCDAI; PEDIATRIC CROHN'S DISEASE ACTIVITY INDEX; PEDIATRIC IBD; PROPENSITY SCORES ANALYSIS; PSA; TNF; TUMOR NECROSIS FACTOR;

6-MERCAPTOPURINE; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CHILD; CHILD DEVELOPMENT; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MALE; MATCHED-PAIR ANALYSIS; METHOTREXATE; PROPENSITY SCORE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84892821247     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.10.027     Document Type: Article

References (23)

1. J. Markowitz, J. Hyams, and D. Mack et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease Clin Gastroenterol Hepatol 4 2006 1124 1129
2. D. Wilson, A. Thomas, and N. Croft et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease J Pediatr Gastroenterol Nutr 50 Suppl 2010 S14 S34
3. J. Markowitz, K. Grancher, and N. Kohn et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology 119 2000 895 902
4. M. Pfefferkorn, G. Burke, and A. Griffiths et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms J Pediatr Gastroenterol Nutr 48 2009 168 174
5. J. Hyams, W. Crandall, and S. Kugathasan et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children Gastroenterology 132 2007 863 873
6. J.S. Hyams, A. Griffiths, and J. Markowitz et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children Gastroenterology 143 2012 365 374
7. G. D'Haens, F. Baert, and G. van Assche et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 2008 660 667
8. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, D. Rachmilewitz, S. Lichtiger, G. D'Haens, R.H. Diamond, D.L. Broussard, K.L. Tang, C.J. van der Woude, and P. Rutgeerts Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
9. J.S. Hyams, G.D. Ferry, and F.S. Mandel et al. Development and validation of a pediatric Crohn's disease activity index J Pediatr Gastroenterol Nutr 12 1991 439 447
10. A. Levine, A. Griffiths, and J. Markowitz et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification Inflamm Bowel Dis 17 2010 1314 1321
11. P. Rosenbaum, and D. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
12. Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee presented on July 23, 2012, and revised thereafter.
13. L.S. Parsons Reducing bias in a propensity score matched-pair sample using greedy matching techniques SAS Institute Inc, Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference 2001 214 226
14. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2012. Available at: http://www.r-project.org/.
15. S. Kugathasan, S.L. Werlin, and A. Martinez et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease Am J Gastroenterol 95 2000 3189 3194
16. P. Lionetti, F. Bronzini, and C. Salvestrini et al. Response to infliximab is related to disease duration in paediatric Crohn's disease Aliment Pharmacol Ther 18 2003 425 431
17. J.R. Rosh, T. Gross, and P. Mamula et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13 2007 1024 1030
18. M. Allez, M. Lemann, and J. Bonnet et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy Am J Gastroenterol 97 2002 947 953
19. V. Crombe, J. Salleron, and G. Savoye et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study Inflamm Bowel Dis 17 2011 2144 2152
20. S. Malik, S.F. Ahmed, and M.L. Wilson et al. The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn's disease (CD) J Crohns Colitis 6 2012 337 344
21. T.D. Walters, A.R. Gilman, and A.M. Griffiths Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease Inflamm Bowel Dis 13 2007 424 430
22. M.C. Dubinsky, S. Lamothe, and H.Y. Yang et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
23. I. Ordas, B.G. Feagan, and W.J. Sandborn Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease Clin Gastroenterol Hepatol 10 2012 1079 1087